The FDA has granted tisagenlecleucel (Kymriah, Novartis) its second indication—the treatment of adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy. The approval includes treatment of diffuse large B-cell lymphoma (DLBCL) as well as high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma, but it does not include primary central nervous system lymphoma.
"This is an exciting event—seeing this lifesaving therapy